Insider · CIK 0001553595
John Patrick Shannon Jr
Files at XERS (Xeris Biopharma Holdings, Inc.). First filing Nov 17, 2023, latest Jan 6, 2026.
In brief
John Patrick Shannon Jr files SEC Form 4 as officer and director at XERS (Xeris Biopharma Holdings, Inc.). Since Nov 17, 2023, John Patrick Shannon Jr has reported 1 open-market buy worth $50k and 2 open-market sells worth $350k, the latest filed on Jan 6, 2026.
A track record needs three past buys with six months of prices behind them; John Patrick Shannon Jr has 0, so none is measured yet.
The newest scored trade: sold $176k of XERS on Jan 5, 2026, filed Jan 6, 2026, scored 7 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $350k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XERS: Xeris Biopharma Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 7Weak | Xeris Biopharma Holdings, Inc. | $176k 24,907 shares | -1% | +122% from low-28% from high | |
| 0Weak | Xeris Biopharma Holdings, Inc. | $173k 23,242 shares | -1% | +150% from low-27% from high | |
| 45Moderate | Xeris Biopharma Holdings, Inc. | $50k 30,769 shares | +2% | +72% from low-41% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 13, 2025 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 48,149 0.03% of outstanding | $365k | Nov 13, 2025 | none |
Transactions
Every row this insider has filed, 21 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -36,645 | $8.08 | $296k | 2,898,933 | Aug 21, 2026 |
| Jan 30, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +478,436 | $0.00 | $0 | 3,276,083 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -118,134 | $7.36 | $869k | 3,157,949 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -111,621 | $7.36 | $822k | 3,046,328 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -110,750 | $7.36 | $815k | 2,935,578 | Feb 2, 2026 |
| Jan 30, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +639,639 | $0.00 | $0 | 639,639 | Feb 2, 2026 |
| Jan 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -24,907 | $7.08 | $176k | 2,705,346 | Jan 6, 2026 |
| Jan 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Common Stock | +64,265 | $1.55 | $100k | 2,769,611 | Jan 6, 2026 |
| Jan 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Common Stock | +25,136 | $1.55 | $39k | 2,794,747 | Jan 6, 2026 |
| Jan 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Common Stock | +2,900 | $3.94 | $11k | 2,797,647 | Jan 6, 2026 |
| Jan 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -64,265 | $0.00 | $0 | 0 | Jan 6, 2026 |
| Jan 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -25,136 | $0.00 | $0 | 0 | Jan 6, 2026 |
| Jan 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -2,900 | $0.00 | $0 | 97,100 | Jan 6, 2026 |
| Nov 13, 2025 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Common Stock10b5-1 | +8,970 | $1.55 | $14k | 2,666,395 | Nov 17, 2025 |
| Nov 13, 2025 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -23,242 | $7.46 | $173k | 2,643,153 | Nov 17, 2025 |
| Nov 14, 2025 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Common Stock | +87,100 | $1.55 | $135k | 2,730,253 | Nov 17, 2025 |
| Nov 13, 2025 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,970 | $0.00 | $0 | 151,365 | Nov 17, 2025 |
| Nov 14, 2025 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -87,100 | $0.00 | $0 | 64,265 | Nov 17, 2025 |
| Aug 1, 2025 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -36,918 | $5.38 | $199k | 2,657,425 | Aug 4, 2025 |
| Jan 31, 2024 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +750,000 | $0.00 | $0 | 2,158,575 | Jan 31, 2024 |
| Nov 17, 2023 | XERS Xeris Biopharma Holdings, Inc. | POpen-market purchase Common Stock | +30,769 | $1.64 | $50k | 1,408,575 | Nov 17, 2023 |
Questions about John Patrick Shannon Jr
Answered from the filings on this page, as of the latest one.
Is John Patrick Shannon Jr buying or selling?
In the last 12 months John Patrick Shannon Jr reported 0 open-market buys worth $0 and 2 open-market sells worth $350k on SEC Form 4; the latest was sold $176k of XERS on Jan 5, 2026. Grants, option exercises and tax withholding are not counted.
How did John Patrick Shannon Jr's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Patrick Shannon Jr has 0.
Where does John Patrick Shannon Jr file Form 4?
John Patrick Shannon Jr has filed Form 4 at XERS (Xeris Biopharma Holdings, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.